Agency in full compliance with section 510 of the FD&C Act before January 9, 2014. As previously stated, drug products covered by this document that are currently marketed but not listed with the Agency on the date of this document must, as of the effective date of this document, have approved applications before their shipment in interstate commerce. Moreover, any person or firm that has submitted or submits an application but has yet to receive approval for such products is still responsible for full compliance with this document.

V. Discontinued Products

Some firms may have previously discontinued manufacturing or distributing products covered by this document without removing them from the listing of their products under section 510(j) of the FD&C Act. Other firms may discontinue manufacturing or distributing listed products in response to this document. Firms are required to electronically update the listing of their products under section 510(j) of the FD&C Act to reflect discontinuation of unapproved products covered by this document (21 CFR 207.21(b)). Questions on electronic drug listing updates should be sent to: *eDRLS@fda.hhs.gov*. In addition to the required update, firms can also notify the Agency of product discontinuation by sending a letter, signed by the firm's chief executive officer and fully identifying the discontinued product(s), including the product NDC number(s), and stating that the manufacturing and/or distribution of the product(s) has (have) been discontinued. The letter should be sent electronically to Astrid Lopez-Goldberg (see **ADDRESSES**). FDA plans to rely on its existing records, including its drug listing records, the results of any subsequent inspections, or other available information when it targets violations for enforcement action.

VI. Reformulated Products

FDA cautions firms against reformulating their products into unapproved new drugs without codeine sulfate, codeine phosphate, or dihydrocodeine bitartrate, and marketing them under the same name or substantially the same name (including a new name that contains the old name) in anticipation of an enforcement action based on this document. As stated in the Marketed Unapproved Drugs CPG, FDA intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an anticipated FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient have the potential to confuse healthcare practitioners and harm patients.

Dated: January 6, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2014–00257 Filed 1–9–14; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Statement of Organization, Functions and Delegations of Authority

This notice amends Part R of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA) (60 FR 56605, as amended November 6, 1995; as last amended at 78 FR 42089–42090 dated July 15, 2013).

This notice reflects organizational changes in the Health Resources and Services Administration. This notice corrects the administrative codes for the Bureau of Clinician Recruitment and Service (RU); the Division of Regional Operations (RU2) and the Office of Business Operations (RU3).

Chapter RU—Bureau of Clinician Recruitment and Service

Section RU–10, Organization

Delete and replace in its entirety.

The Office of the Associate Administrator (RU) is headed by the Associate Administrator, Bureau of Clinician Recruitment and Service (BCRS), who reports directly to the Administrator, Health Resources and Services Administration. BCRS includes the following components:

(1) Office of the Associate Administrator (RU);

(2) Office of Legal and Compliance (RU1);

(3) Division of Regional Operations (RU2);

(4) Office of Business Operations (RU3);

(5) Division of National Health Service Corps (RU5);

(6) Division of Nursing and Public Health (RU6);

(7) Division of External Affairs (RU7);

(8) Division of Policy and Shortage Designation (RU8); and

(9) Division of Program Operations (RU9).

Section RU–30, Delegations of Authority

All delegations of authority and re-delegations of authority made to HRSA officials that were in effect immediately prior to this reorganization, and that are consistent with this reorganization, shall continue in effect pending further re-delegation.

This reorganization is effective upon date of signature.

Dated: December 26, 2013.

Mary K. Wakefield,

Administrator.

[FR Doc. 2014–00221 Filed 1–9–14; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Organization, Function, and Delegations of Authority; Part G; Proposed Functional Statement

AGENCY: Indian Health Service, HHS.

ACTION: Notice of change in name of an organizational component.

SUMMARY: The Indian Health Service is announcing the name change of the Aberdeen Area Indian Health Service to the Great Plains Area Indian Health Service at the request of Tribes served by the Aberdeen Area Indian Health Service.

FOR FURTHER INFORMATION CONTACT: Ms. Mona Galpin, Office of Management Services, Management Policy and Internal Control Staff, 801 Thompson Avenue, TMP Suite 625A, Rockville, MD 20852, Telephone 301–443–2650.

Section GF–10, Indian Health Service Area Offices—Organization

An Area Office is a second echelon organization under the direction of an Area Director, who reports to the IHS Director.

Indian Health Service Area Offices of the Indian Health Service in alphabetical order:

- Alaska Area Office (GFB)
- Albuquerque Area Office (GFC)
- Bemidji Area Office (GFE)
- Billings Area Office (GFF)
- California Area Office (GFG)
- Great Plains Area Office (GFA)
- Nashville Area Office (GFH)
- Navajo Area Office (GFJ)
- Oklahoma Area Office (GFK)
- Phoenix Area Office (GFL)
- Portland Area Office (GFM)
- Tucson Area Office (GFN)